The unique physicochemical characteristics of nanoparticles have recently gained
increasing attention in a diverse set of applications, particularly in the biomedical field …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

The emergence of drug resistance limits the efficacy of targeted therapies in human tumors.
The prevalent view is that resistance is a fait accompli: when treatment is initiated, cancers …

Oncogene activation disturbs cellular processes and accommodates a complex landscape
of changes in the genome that contribute to genomic instability, which accelerates mutation …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Reactive oxygen species (ROS) play an important role in determining the fate of normal
stem cells. Low levels of ROS are required for stem cells to maintain quiescence and self …

'Reactive species'(RS) of various types are formed in vivo and many are powerful oxidizing
agents, capable of damaging DNA and other biomolecules. Increased formation of RS can …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …